LONDON, March 16 (Reuters) - Adding GlaxoSmithKline Plc's top-selling drug Advair to Pfizer Inc's Spiriva does not reduce exacerbations in patients with COPD, or smoker's lung, according to new ...
According to Nuvama, the increased competitive intensity following this approval is negative for Cipla, as it raises the risk ...
LONDON (Reuters) - GlaxoSmithKline's top-selling respiratory drug Advair is set to lose business to Spiriva, marketed by Pfizer and Boehringer Ingelheim, according to analysts at Morgan Stanley. Sign ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
A mixed day for GlaxoSmithKline's respiratory franchise saw the UK major get the thumbs-up from the US Food and Drug Administration for its chronic obstructive pulmonary disease drug Anoro but Danish ...
October 27, 2006 (Salt Lake City) -- New findings from the landmark Towards a Revolution in COPD Health (TORCH) study show that high-dose inhaled fluticasone propionate 500 mg/salmeterol 50 mg ( ...
(Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback